Y-m Abs announces positive data for naxitamab and GM-CSF joint clinical trial

recently, Y-mAbs(http:// announcedthat its humanized monoclonal antibody naxitamab, a humanoid monoclonal antibody to GD2 antigens, was combined with GM-CSF to obtain positive efficacy and safety data in clinicaltrial(http://treating children with neuroblastoma and osteosarcomaAbout NaxitamabNaxitamab is a humanoid monoclonal antibody that targets GD2 antigensGD2 antigens are expressed on tumor surfaces produced in the neuroblastoma layer, including neuroblastoma, melanoma and osteosarcomaBy binding to GD2 antigens on the tumor surface, Naxitamab can trigger a cytotoxic reaction of antibody vectors and activate the immune system's complement system to kill tumorsIt has been granted an orphan drug by theFDA(http://for the treatment of neuroblastoma and osteosarcoma, and breakthrough therapy has been identified as a combination of GM-CSF for the treatment of high-risk neuroblastomacurrently, the Naxitamab is currently used in clinical trials to treat children with recurrent/difficult-treatment high-risk neuroblastoma, osteosarcoma, and other GD2-positive tumorsthe studyin the first group of children with neuroblastoma in phase 12-230 clinical trials, 28 patients at high risk of relapsing/difficult treatment who were not eligible for induced chemotherapy received a combination of naxitamab and GM-CSF, and more than half of them were also less likely to receive second-line chemotherapy trial data show that the combination of therapies resulted in a 78 percent objective remission rate (ORR) for patients and a 24-month non-progressive survival (PFS) in 50 percent of patients 　　In subgroups of children in the second group of neuroblastoma patients in the 12-230 trial, 30 patients who received salvage therapy but did not perform well received a combination of naxitamab and GM-CSF, with one-third having relapsed more than twice and 89 percent receiving anti-GD2 drug (http:// trial data show that the combination of therapies caused 37 percent orR in patients and 36 percent of patients with PFS to 24 months, bringing significant clinical benefits to patients with this type of incurable type